Next week on the invitation of Valerie Paris, an economist working on health policies in the Directorate for Employment, Labour and Social Affairs at OECD (Paris), I will give a seminar on “Economic analysis of the Orphan Drug market”, where I will discuss the impact of OD legislation on sustaining OD research via improved fund-raising capacities of the biotechnology firms.